Vizsgálati helyszín
Centro Hospitalar de Vila Nova de Gaia Espinho E P E
Vila Nova de Gaia, 4434 502, PortugáliaMég nincs intézményhez kötve
- 15futó vizsgálat
- 17lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 32 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis26 vizsgálat
- 2. fázis3 vizsgálat
- 1. fázis2 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Lezárult17 vizsgálat
- Fut, nem toboroz12 vizsgálat
- Meghívásos bevonás1 vizsgálat
- Még nem toboroz1 vizsgálat
- Toboroz1 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC3 vizsgálat
- Novartis Pharmaceuticals3 vizsgálat
- Abivax S.A.2 vizsgálat
- Novartis Pharma AG2 vizsgálat
- AstraZeneca1 vizsgálat
- és még 21
Futó vizsgálatok
Meghívásos bevonás
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06723106· 1. fázis· Chugai Pharmaceutical· Forrás
Fut, nem toboroz
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines
2023-505739-12-01· 3. fázis· Novartis Pharma AG· Forrás
Fut, nem toboroz
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801· 3. fázis· Gossamer Bio USA, Inc.· Forrás
Még nem toboroz
A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia
2023-508981-13-00· 1. fázis· Geneora Pharma (Shijiazhuang) Co. Ltd.· Forrás
Fut, nem toboroz
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744· 3. fázis· Genmab· Forrás
Toboroz
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2)
2022-500700-22-00· 3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
ABTECT - Maintenance
NCT05535946· 3. fázis· Abivax S.A.· Forrás
Fut, nem toboroz
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252· 3. fázis· AstraZeneca· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome
2023-503923-24-00· 3. fázis· Horizon Therapeutics Ireland Designated Activity Company· Forrás
Lezárult
A proof of concept and dose-finding study of XXB750 in patients with heart failure
2023-504678-39-00· 2. fázis· Novartis Pharma AG· Forrás
Lezárult
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526· 3. fázis· GB002, Inc.· Forrás
Lezárult
Initiation of ARNi and SGLT2i in Patients With HFrEF
NCT05989503· 4. fázis· Universidade do Porto· Forrás
Lezárult
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
NCT05911360· 3. fázis· ViiV Healthcare· Forrás
Fut, nem toboroz
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)
2023-508528-36-00· 3. fázis· Merck Healthcare KGaA· Forrás
Lezárult
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke
NCT05643573· 3. fázis· Bayer AG· Forrás
Lezárult
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
NCT05610280· 3. fázis· Ionis Pharmaceuticals, Inc.· Forrás
Lezárult
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203· 3. fázis· Abivax S.A.· Forrás
Lezárult
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
NCT05437263· 3. fázis· Priovant Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· 2. fázis· Janssen Research & Development, LLC· Forrás
Leállították
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646· 3. fázis· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás
Lezárult
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia.
2021-002192-19· 3. fázis· Ionis Pharmaceuticals Inc.· Forrás
Lezárult
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
NCT04596631· 3. fázis· Novo Nordisk A/S· Forrás
Hibát jelzek